What is BPC-157?
BPC-157 is an experimental peptide, meaning a short chain of amino acids. In this case there are fifteen. Scientists are examining how it affects processes involved in tissue damage and repair. Online, it is often labelled as a recovery substance, but that label does not itself establish treatment effectiveness. [50]
It helps to separate three questions: does the substance trigger a response in cells, does it improve human health, and do the benefits outweigh the risks? Each requires different studies. For BPC-157, convincing answers to the last two are particularly lacking.
Why are researchers interested in tendons?
One experiment studied cells and fragments of rat Achilles tendon. BPC-157 affected cell movement and survival under adverse conditions, among other things. This may help explain repair processes. It does not establish whether a person with an injured tendon will recover function sooner. [47]
Laboratory tissue does not perform everyday work or exercise. Nor does it reproduce a person's whole condition, other medicines or physical demands. An experimental finding is therefore a starting point for further research, not a ready-made treatment.
What has been tested in humans?
In a small observation of people with knee pain, 11 of 12 patients who received BPC-157 alone reported improvement. However, there was no comparison group. It is therefore impossible to establish how much of the change came from the substance, the natural course of the problem or other circumstances. Less pain is not proof of cartilage repair either. [48]
How was the knee observation carried out?
Records for 17 people were reviewed, and 16 could be reached by telephone. Twelve received BPC-157 alone and four received a combination with TB4. These results should not be combined as the effect of BPC-157 alone. Standard tools for assessing function were not used. We reviewed the abstract, the authors' summary. [48]
The FDA's 2026 assessment also included older, sparsely described studies of other health problems. Their existence does not establish a treatment for sports injuries. The quality and scope of the evidence matter, not simply the number of publications. [50]
Do we know the risks?
It is not sufficiently understood. In a pilot published in 2025, two people reported no adverse effects during brief follow-up. This is far too small to detect rare problems or long-term effects. Both participants had previously received BPC-157. [49]
Product quality is a separate issue: actual contents, impurities and sterility. The TGA warns about this in its unapproved-peptides notice. Missing good risk data are not equivalent to demonstrated safety. [53]
Does a change in regulations mean a medicine is approved?
No. In late October 2026, the USA published a draft policy on compounding selected preparations for individual prescriptions, including BPC-157 acetate. This is a different kind of decision from approving a finished medicine after assessing its effectiveness and safety. It is not a decision authorising a product in Poland either. [51] [52]
What should athletes know?
The 2026 WADA List names BPC-157 as prohibited at all times, including outside competition. An anti-doping ban does not prove that a preparation effectively treats an injury. However, it is important separate information for athletes subject to those rules. [54]
What should you read next?
BPC-157: new reports and the limits of the evidence — we explain what has actually changed in our knowledge and how to read information about regulations.
Where does this information come from?
Show sources and how they were checked
- FDA: ocena BPC-157 dla komisji doradczej
US regulator · assessment dated 11 May 2026, meeting in July 2026 · selected sections on research, safety and status. Accessed: 2 November 2026.
- Chang et al.: BPC-157 and rat tendon cells
Preclinical study · 2011 · abstract reviewed. Accessed: 2 November 2026.
- Lee and Padgett: BPC-157 for different types of knee pain
Retrospective patient observation · 2021 · abstract reviewed. Accessed: 2 November 2026.
- Lee and Burgess: BPC-157 safety pilot in two people
Small pilot study · 2025 · abstract read. Accessed: 02.11.2026.
- TGA: niezatwierdzone produkty peptydowe
Australian regulator · 13.04.2026 · main announcement text. Accessed: 02.11.2026.
- HHS: announcement of a draft policy on peptide compounding
Federal Register, US · 30 October 2026 · full announcement; a draft, not drug approval. Accessed: 2 November 2026.
- HHS: draft policy and appendices concerning peptides
US document · October 2026 · policy and sections concerning the substances discussed. Accessed: 2 November 2026.
- WADA: Lista substancji i metod zabronionych 2026
Official list · effective from 1 January 2026 · relevant sections for the substances discussed. Accessed: 2 November 2026.